The development of tyrosine kinase inhibitors (TKIs), which effectively disrupted the interaction between the BCR::ABL1 oncoprotein and adenosine triphosphate, significantly altered the therapeutic landscape of CML. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.